XLO
Xilio Therapeutics, Inc. NASDAQ Listed Oct 22, 2021$9.05
+0.11%
vs $9.04
Mkt Cap $756.5M
52w Low $7.14
38.7% of range
52w High $12.08
50d MA $9.03
200d MA $8.59
P/E (TTM)
-5.5x
EV/EBITDA
—
P/B
21.4x
Debt/Equity
0.2x
ROE
-99.3%
P/FCF
-137.3x
RSI (14)
59.50
ATR (14)
$0.24
Beta
-0.12
50d MA
$9.03
200d MA
$8.59
Avg Volume
11.0K
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
828 Winter Street · Waltham, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | TNS | -0.59 | -0.33 | +44.1% | 9.05 | +0.0% | -0.4% | +1.8% | +3.5% | +0.1% | -0.9% | — |
| May 12, 2026 | TNS | -0.66 | -0.58 | +12.1% | 7.73 | +2.2% | +0.4% | +13.5% | -5.1% | -2.5% | +0.4% | — |
| Mar 23, 2026 | TNS | -1.68 | -0.85 | +49.4% | 7.86 | -0.8% | +6.5% | +1.9% | +1.8% | -4.1% | -1.0% | — |
| Nov 13, 2025 | TNS | -0.45 | -0.03 | +93.3% | 9.82 | -5.9% | +0.8% | +2.4% | +3.6% | +7.6% | -7.1% | — |
| Aug 14, 2025 | TNS | -1.10 | -0.16 | +85.5% | 9.84 | +1.0% | +0.9% | -0.3% | -3.6% | -2.6% | +1.0% | — |
| May 8, 2025 | TNS | -2.70 | -0.18 | +93.3% | 10.08 | -1.4% | -1.4% | +2.9% | +57.4% | -26.1% | -5.9% | — |
| Mar 11, 2025 | TNS | -3.03 | -0.20 | +93.4% | 11.10 | -0.4% | +4.1% | -3.1% | +0.1% | +0.9% | -4.0% | — |
| Nov 7, 2024 | TNS | -0.25 | -0.22 | +12.0% | 14.56 | -4.8% | -4.8% | +10.1% | -0.9% | -7.6% | -4.1% | — |
| Aug 8, 2024 | TNS | -0.23 | -0.24 | -4.3% | 12.03 | +0.7% | +0.9% | -3.8% | -4.7% | +3.8% | +0.6% | — |
| May 14, 2024 | TNS | -0.11 | -0.62 | -463.6% | 15.26 | +0.0% | +2.8% | -3.6% | +5.6% | +9.6% | -4.0% | — |
| Apr 1, 2024 | TNS | -0.64 | -0.64 | +0.0% | 21.42 | -7.2% | -3.3% | -12.2% | -6.9% | -0.8% | +22.5% | — |
| Nov 9, 2023 | TNS | -0.81 | -0.61 | +24.7% | 22.40 | +9.4% | -10.6% | -1.4% | -7.1% | +2.3% | -2.6% | — |
| Aug 14, 2023 | AMC | -0.87 | -0.70 | +19.5% | 40.04 | -3.5% | +0.3% | -3.0% | -3.4% | -2.6% | +5.7% | — |
| May 9, 2023 | AMC | -0.89 | -0.83 | +6.7% | 44.80 | -3.1% | +0.0% | +0.0% | -0.9% | -3.2% | +2.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 8 | Raymond James | Maintains | Outperform → Outperform | — | $14.56 | $13.86 | -4.8% | -4.8% | +10.1% | -0.9% | -7.6% | -4.1% |
| May 30 | Chardan Capital | Maintains | Buy → Buy | — | $42.84 | $45.50 | +6.2% | -0.3% | +0.0% | -4.6% | +2.4% | +3.5% |
| Jan 27 | Morgan Stanley | Maintains | Overweight → Overweight | — | $57.82 | $56.00 | -3.1% | +3.6% | -7.2% | -8.1% | +1.4% | +0.8% |
| Nov 10 | Raymond James | Maintains | Outperform → Outperform | — | $32.06 | $32.06 | +0.0% | +6.6% | +2.3% | -1.4% | -2.4% | +9.2% |
| Aug 10 | Morgan Stanley | Maintains | Overweight → Overweight | — | $33.88 | $33.04 | -2.5% | +2.1% | +2.0% | -2.4% | -0.4% | -0.4% |
No insider trades available.
8-K · 2.02
!! High
Xilio Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Aug 12
8-K · 2.02
!! High
Xilio Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Xilio Therapeutics reported financial results and operational updates via press release, with full details available in the furnished exhibit for investor review.
May 12
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Dr. Blanchard's director compensation includes stock options vesting over three years, signaling board continuity and potential shareholder dilution as equity grants represent ongoing compensation costs.
Apr 16
8-K
Unknown — 8-K Filing
Axsome Therapeutics (XLO) announced Q4 2025 pipeline progress in immuno-oncology, signaling clinical advancement that could drive future revenue growth and reduce cash burn concerns for investors monitoring the biotech's clinical-stage programs.
Mar 23
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
XLO implemented a reverse stock split eliminating fractional shares, likely to raise stock price and meet listing requirements, which could signal financial distress or delisting risk to investors.
Mar 12
8-K · 7.01
! Medium
Xilio Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Xilio Therapeutics updated its corporate investor presentation on its website, providing current business information to investors through its investor relations portal.
Mar 9
8-K
Xilio Therapeutics, Inc. -- 8-K Filing
I cannot provide a meaningful analysis because the filing summary lacks substantive information about a material corporate event, deal, or announcement involving Xilio Therapeutics.
Feb 24
8-K · 7.01
! Medium
Xilio Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Xilio Therapeutics (XLO) announced pricing details for a securities offering on February 11, 2026, with full terms disclosed in the attached press release exhibit.
Feb 12
Institutional (13F) — Top 12
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 178,517 | $2M | Added | Jun 2026 |
| 2 | Renaissance Technologies Llc | 64,153 | $615K | Added | Jun 2026 |
| 3 | Citadel Advisors Llc | 51,900 | $497K | New | Jun 2026 |
| 4 | Fmr Llc | 36,558 | $307K | New | Mar 2026 |
| 5 | Two Sigma Investments, Lp | 14,544 | $139K | New | Jun 2026 |
| 6 | Velan Capital Investment Management Lp | 14,285 | $137K | — | Jun 2026 |
| 7 | Blackrock, Inc. | 8,757 | $84K | New | Jun 2026 |
| 8 | Cwm, Llc | 4,206 | $35K | New | Mar 2026 |
| 9 | Ubs Group Ag | 4,038 | $34K | New | Mar 2026 |
| 10 | Jpmorgan Chase & Co | 240 | $2K | New | Mar 2026 |
| 11 | Royal Bank Of Canada | 91 | $1K | New | Mar 2026 |
| 12 | Key Financial Inc | 59 | $565 | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Series Total Market Index Fund | 7,476 | $63K | May 2026 |
| 2 | Fidelity Total Market Index Fund | 4,514 | $38K | May 2026 |
| 3 | Guggenheim Active Allocation Fund | 43 | $23 | Feb 2026 |
Valuation
Market Cap
$756.5M
Enterprise Value
$619.0M
P/E (TTM)
-5.52x
Forward P/E
—
PEG Ratio
0.29x
P/B
21.45x
P/S
11.80x
P/FCF
-137.30x
EV/EBITDA
—
Shares Out
83.6M
Financials (TTM)
Revenue
$64.1M
Net Income
-$21.8M
EBITDA
-$20.5M
Free Cash Flow
-$5.5M
Op Cash Flow
-$5.0M
EPS Basic
$-4.19
EPS Diluted
$-1.64
EPS Forward
$-2.39
Gross Margin
99.5%
Op Margin
-48.9%
Net Margin
-34.1%
Balance Sheet
Total Assets
$154.7M
Total Liab.
$119.4M
Total Equity
$35.3M
Cash
$137.5M
LT Debt
$0
Book Value/Sh
$0.42
Debt/Equity
0.20x
Current Ratio
2.58
Quick Ratio
2.58
Returns & Growth
ROE
-99.3%
ROA
-22.7%
ROIC
-42.1%
Rev Growth YoY
+589.9%
EPS Growth YoY
+72.5%
Price Returns
2W
+1.2%
1M
-0.1%
3M
-0.1%
6M
+4.1%
12M
-18.9%
Technicals
52W High
$12.08
52W Low
$7.14
50d MA
$9.03
200d MA
$8.59
RSI (14)
59.50
ATR (14)
$0.24
Beta
-0.12
Avg Volume
11K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$98.00
High
$98.00
Low
$98.00
Median
$98.00
Data updated apr 27, 2026 10:35am
· Source: financialmodelingprep.com